Last reviewed · How we verify
Liposomal bupivacaine plus bupivacaine
Liposomal bupivacaine plus bupivacaine is a Small molecule drug developed by Beijing Tiantan Hospital. It is currently FDA-approved. Also known as: LB+B.
At a glance
| Generic name | Liposomal bupivacaine plus bupivacaine |
|---|---|
| Also known as | LB+B |
| Sponsor | Beijing Tiantan Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- EOIFP Block Versus OSTAP Block for Upper Abdominal Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery in Gynecologic Oncology (NA)
- The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Laparoscopic Surgery (NA)
- Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG) (PHASE4)
- Liposomal Bupivacaine With Standard Bupivacaine Versus Dexmedetomidine With Standard Bupivacaine (PHASE3)
- EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement (PHASE2)
- The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liposomal bupivacaine plus bupivacaine CI brief — competitive landscape report
- Liposomal bupivacaine plus bupivacaine updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI
Frequently asked questions about Liposomal bupivacaine plus bupivacaine
What is Liposomal bupivacaine plus bupivacaine?
Liposomal bupivacaine plus bupivacaine is a Small molecule drug developed by Beijing Tiantan Hospital.
Who makes Liposomal bupivacaine plus bupivacaine?
Liposomal bupivacaine plus bupivacaine is developed and marketed by Beijing Tiantan Hospital (see full Beijing Tiantan Hospital pipeline at /company/beijing-tiantan-hospital).
Is Liposomal bupivacaine plus bupivacaine also known as anything else?
Liposomal bupivacaine plus bupivacaine is also known as LB+B.
What development phase is Liposomal bupivacaine plus bupivacaine in?
Liposomal bupivacaine plus bupivacaine is FDA-approved (marketed).
Related
- Manufacturer: Beijing Tiantan Hospital — full pipeline
- Also known as: LB+B
- Compare: Liposomal bupivacaine plus bupivacaine vs similar drugs
- Pricing: Liposomal bupivacaine plus bupivacaine cost, discount & access